A Phase 3, Double-blind, Randomized, Placebo controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-031

To Learn More Call
201-510-0910